Skip to main content

Table 2 Relapse rate and rebound rate

From: Oral PSORI-CM01, a Chinese herbal formula, plus topical sequential therapy for moderate-to-severe psoriasis vulgaris: pilot study for a double-blind, randomized, placebo-controlled trial

Group

 

Treatment success

relapse

rebound

 

n

PASI-50

Never PASI-50

relapse

No relapse

rebound

No rebound

CHM

7

6 (86 %)

1 (14 %)

1 (17 %)

5 (83 %)

0 (0 %)

6 (100 %)

Placebo

10

9 (90 %)

1 (10 %)

6 (67 %)

3 (33 %)

0 (0 %)

9 (100 %)

Total

17

15

2

7

8

0

15

  1. CHM Chinese herbal medicine
  2. PASI-50, PASI score decreases more than 50 % from baseline
  3. Relapse, loss of 50 % of PASI improvement from baseline in patients who have achieved treatment success (at least 50 % improvement in PASI score from baseline)
  4. Rebound, defined only for patients who achieved PASI-50, occurred when the improvement in the PASI score increased up to 25 % from the baseline PASI score
  5. There was no difference in the relapse rate between the two groups by Chi-square (odds ratio: 0.10; 95 % CI: 0.008, 1.288; P = 0.119)